Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663483 | 1.00 | HTT (0.64) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL29224064 | 0.85 | HTT (0.50) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL27223540 | 0.81 | DCPS (0.53) | — | |
| SCHEMBL21500731 | 0.81 | HTT (0.68) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL1991118 | 0.81 | BCHE (0.42) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL29441517 | 0.81 | HTT (0.68) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL29909019 | 0.81 | BCHE (0.42) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL4852768 | 0.80 | HTT (0.47) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL8897424 | 0.78 | HTT (1.00) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL3778992 | 0.78 | HTT (0.64) | HTTACHEBCHEGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2021-11-18 | — | — | US | disclosed |
| WO-2019204768-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353626-A1 | BETA-ADRENERGIC RECEPTOR ALLOSTERIC MODULATORS | ADRB1, ADRB2, ADRA2B | HTT 4394/4885ACHE 605/4885BCHE 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.